Tianjin Lisheng Pharmaceutical Co.,Ltd.
Simbols: 002393.SZ
SHZ
25.45
CNYTirgus cena šodien
12.3975
P/E koeficients
7.8104
PEG koeficients
4.64B
MRK Cap
- 0.01%
DIV ienesīgums
Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393-SZ) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 8384.27 | 2220.2 | 1993.6 | 1651.9 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 371.13 | 231.3 | 200.3 | -31.9 | ||||||||||||||||||
balance-sheet.row.net-receivables | 1996.79 | 321.5 | 427.7 | 461.9 | ||||||||||||||||||
balance-sheet.row.inventory | 779.47 | 176.3 | 199.1 | 228.8 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 449.96 | 100.5 | 4.9 | 13.9 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 11610.5 | 2818.5 | 2625.4 | 2356.4 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 4045.76 | 981.9 | 1029.8 | 1136.7 | ||||||||||||||||||
balance-sheet.row.goodwill | 57.92 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 567.45 | 124.9 | 135.5 | 144.2 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 625.37 | 124.9 | 135.5 | 144.2 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 6115.65 | 1810.6 | 1180.6 | 1531.8 | ||||||||||||||||||
balance-sheet.row.tax-assets | 134.98 | 39.5 | 33.7 | 16.3 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 177.12 | 5.3 | 286.1 | 5.5 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 11098.87 | 2962.1 | 2665.6 | 2834.5 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 22709.37 | 5780.6 | 5291 | 5190.9 | ||||||||||||||||||
balance-sheet.row.account-payables | 331.1 | 84.8 | 146.4 | 90.5 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 228.64 | 59.1 | 39.7 | 28.5 | ||||||||||||||||||
balance-sheet.row.tax-payables | 149.6 | 14.6 | 42.5 | 20.3 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 17.77 | 3.9 | 5.4 | 6.2 | ||||||||||||||||||
Deferred Revenue Non Current | 117.89 | 27.9 | 31.8 | 31.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 741.36 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 1093.6 | 467.4 | 543.9 | 1.4 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 906.67 | 223 | 211.7 | 228 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 17.77 | 3.9 | 5.4 | 6.2 | ||||||||||||||||||
balance-sheet.row.total-liab | 3750.51 | 849.2 | 941.7 | 780.4 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 736.51 | 184.3 | 184 | 182.5 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 5422.19 | 1393.7 | 1126.6 | 1098 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 9405.31 | 1612 | 1328.7 | 1439.4 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3334.68 | 1713.4 | 1710.1 | 1690.7 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 18898.68 | 4903.4 | 4349.4 | 4410.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 22709.37 | 5780.6 | 5291 | 5190.9 | ||||||||||||||||||
balance-sheet.row.minority-interest | 32.24 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-equity | 18930.92 | 4903.4 | 4349.4 | 4410.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 22709.37 | - | - | - | ||||||||||||||||||
Total Investments | 6486.78 | 2041.9 | 1380.9 | 1499.8 | ||||||||||||||||||
balance-sheet.row.total-debt | 246.41 | 63 | 45.1 | 34.7 | ||||||||||||||||||
balance-sheet.row.net-debt | -7705.06 | -1925.9 | -1748.2 | -1617.2 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 374.48 | 361.8 | 93.6 | 122.1 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | -0.02 | 67.3 | 66.1 | 60.2 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -36.38 | -5.5 | -15.4 | -8.7 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 8.97 | -136.5 | 15.4 | 8.7 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 29.92 | 1.6 | 137.9 | 17.6 | ||||||||||||||||||
cash-flows.row.account-receivables | 17.52 | 17.5 | 25.1 | -19.5 | ||||||||||||||||||
cash-flows.row.inventory | 8.91 | 8.9 | 11.1 | -4.4 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -28.3 | 117 | 50.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 3.49 | 3.5 | -15.4 | -8.7 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | -128.58 | -79.3 | 33.8 | -3.6 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 245.52 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -59.66 | -61.7 | -40.9 | -88.2 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 147.74 | 151.5 | 115.3 | 0.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -580 | -470 | -320 | -70 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 339.7 | 390 | 90 | 82 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 31.53 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -120.69 | 9.9 | -155.6 | -76.1 | ||||||||||||||||||
cash-flows.row.debt-repayment | -22.45 | 0 | -0.1 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -6.29 | -54.7 | -54.7 | -18.2 | ||||||||||||||||||
cash-flows.row.other-financing-activites | -65.85 | 5.9 | 21 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -143.04 | -48.8 | -33.8 | -18.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 30.37 | 25.1 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | -7.46 | 195.7 | 142 | 102 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 7910.84 | 1989 | 1769.6 | 1627.7 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 7918.29 | 1793.3 | 1627.7 | 1525.7 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 245.52 | 209.5 | 331.4 | 196.3 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -59.66 | -61.7 | -40.9 | -88.2 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 185.86 | 147.8 | 290.5 | 108.1 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1170.61 | 1130.2 | 1146.6 | 1091.9 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 515.47 | 495.6 | 486.3 | 454.5 | ||||||||||||||||||
income-statement-row.row.gross-profit | 655.14 | 634.5 | 660.3 | 637.5 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 103.47 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 24.94 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 314.2 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -29.02 | -13.8 | 108.4 | 96.1 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 564.73 | 521.9 | 576.8 | 591.8 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 1080.2 | 1017.5 | 1063.1 | 1046.3 | ||||||||||||||||||
income-statement-row.row.interest-income | -29.87 | 61.2 | 68.3 | 87.6 | ||||||||||||||||||
income-statement-row.row.interest-expense | 1.54 | 0.9 | 0.9 | 0.3 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 314.2 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 49.9 | 296.6 | -57.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -29.02 | -13.8 | 108.4 | 96.1 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 49.9 | 296.6 | -57.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 1.54 | 0.9 | 0.9 | 0.3 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | -194.14 | 67.3 | 66.1 | 75.8 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | 175.88 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | 370.02 | 112.6 | 175.7 | 136.9 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 419.92 | 409.2 | 118.4 | 137.1 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 57.56 | 58.4 | 24.8 | 15 | ||||||||||||||||||
income-statement-row.row.net-income | 374.48 | 361.8 | 93.6 | 122.1 |
Biežāk uzdotie jautājumi
Kas ir Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) kopējie aktīvi?
Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) kopējie aktīvi ir 5780604152.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 594641936.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.560.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 1.019.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.320.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.316.
Kāda ir Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 361827990.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 63035414.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 521915434.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 1952585069.000.